Delays for the regulatory filings of its Covid-19 vaccine NVX-CoV2373 (NUVAXOVID) have meant Novavax (NVAX) has been unable to get its offering out to the public yet. You would think that with other leading players firmly planted in the public and health policy makers’ consciousness, maybe the opportunity has already passed for last year’s outstanding performer.
However, in late-stage studies, the vaccine’s data has shown to be just as good as those of the leading approved vaccines….
Source link